A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
Completed
Pfizer
Phase 4
2005-07-01
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol
given in the evening time once a day vs the combination of dorzamalide and timolol twice a
day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week
treatment.
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
Completed
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4
2005-07-01
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol
given in the evening time once a day vs the combination of dorzamalide and timolol twice a
day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week
treatment.
To compare the 24-hour efficacy and safety, measured every three hours, of the
dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each
given once daily.
To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol
maleate fixed combination because they are insufficiently controlled on latanoprost
monotherapy.
To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed
combination given twice daily versus bimatoprost given once every evening in patients with
open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
